Treatment Guidelines: Neurocognitive Disorders

Alzheimer's Association

• Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings (2025)

American Psychiatric Association (APA)

• Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias (guideline watch, 2014)
• Practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia (2016)

American Psychological Association

• APA Guidelines for the Evaluation of Dementia and Age-Related Cognitive Change (2021)

British Association for Psychopharmacology (BAP)

• Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology (2017)

Canadian Coalition for Seniors’ Mental Health

• Canadian Clinical Practice Guidelines for Assessing and Managing Behavioural and Psychological Symptoms of Dementia (2024)

Deprescribing Guidelines in the Elderly Project

• Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia (2018)
• Evidence-based clinical practice guidelines for deprescribing cholinesterase inhibitors and memantine: recommendations (2018)

Indian Psychiatric Society (IPS)

• Clinical Practice Guidelines for Management of Dementia (2018)

National Institute for Health and Care Excellence (NICE)

• Dementia: assessment, management and support for people living with dementia and their carers (2018)

World Federation of Societies of Biological Psychiatry (WFSBP)

• Guidelines for the biological treatment of Alzheimer’s disease and other dementias (2011)

World Health Organization (WHO)

• Risk Reduction of Cognitive Decline and Dementia (2019)
• Clinical guidance developed by the Alzheimer’s Disease and Related Disorders Therapeutics Working Group and the FDA Prescribing Information Journal for Prevention of Alzheimer’s Disease Donanemab Appropriate Use Recommendations
• Lecanemab Appropriate Use Recommendations (AUR)

Reviewer 1: Thea Moore, PharmD, BCPP
Reviewer 2: Amanda Campbell, PharmD, BCPP
2025-2026 AAPP Resident and New Practitioner Committee